FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087400259> ?p ?o ?g. }

• W3087400259 endingPage "e807" @default.
• W3087400259 startingPage "e798" @default.
• W3087400259 abstract "Background Obinutuzumab monotherapy has shown promising efficacy in mantle cell lymphoma. We aimed to investigate the activity of obinutuzumab plus DHAP (dexamethasone, high-dose cytarabine, and cisplatin), measured by minimal residual disease quantitative (q)PCR status in the bone marrow after four cycles. Methods LyMa-101 was a prospective, open-label, single-arm, phase 2 trial. Participants were enrolled from 28 hospitals in France. Newly diagnosed patients with mantle cell lymphoma (aged 18 to <66 years) who were eligible for autologous stem-cell transplantation received four cycles of obinutuzumab plus DHAP (obinutuzumab 1000 mg/m2 intravenously on days 1, 8, and 15 at cycle 1 and day 1 at cycles 2, 3, and 4; dexamethasone 40 mg intravenously on days 1–4, cytarabine 2 g/m2 intravenously every 12 h on day 1, and according to local investigator, cisplatin 100 mg/m2 by continuous infusion over 24 h on day 1 or carboplatin area under the curve 5 or oxaliplatin 130 mg/m2) every 21 days before transplantation, and 3 years of obinutuzumab (1000 mg/m2 every 2 months) maintenance followed by minimal residual disease-based obinutuzumab on-demand maintenance. The primary outcome was minimal residual disease negativity in the bone marrow after four cycles of obinutuzumab plus DHAP at the end of induction, measured in the efficacy set (all minimal residual disease-informative [bone marrow or peripheral blood] patients who received at least one dose of obinutuzumab). Obinutuzumab plus DHAP was considered effective if bone marrow minimal residual disease negativity was 70% or more by intention to treat. The trial is closed to recruitment and registered with ClinicalTrials.gov, NCT02896582. Findings 86 patients were enrolled between Nov 29, 2016, and May 2, 2018. 81 patients completed induction, 73 underwent autologous stem-cell transplantation, and 69 started maintenance therapy. 55 (75%) of 73 patients in the efficacy set reached minimal residual disease negativity in bone marrow at end of induction. According to the protocol definition, 18 (25%) of 73 patients in the efficacy set were minimal residual disease-positive: 12 patients who were minimal residual disease-positive in the bone marrow, plus two patients who progressed during induction, and four patients who did not have minimal residual disease assessment. The most common grade 3–4 treatment-emergent adverse events were anaemia (grade 3, 26 [31%] of 85 patients; grade 4, three [4%] of 85 patients) and neutropenia (grade 3, 13 [15%] of 85 patients; grade 4, 32 [38%] of 85 patients). 58 serious adverse events occurred during the induction phase. There were no treatment-related deaths. Interpretation Obinutuzumab plus DHAP is a well tolerated regimen and has good activity for inducing minimal residual disease negativity in the bone marrow of transplant-eligible patients with mantle cell lymphoma. Obinutuzumab plus DHAP has potential activity as induction chemotherapy, with bone marrow minimal residual disease negativity potentially predicting long-term disease control. Funding Roche SAS." @default.
• W3087400259 created "2020-09-25" @default.
• W3087400259 creator A5003078312 @default.
• W3087400259 creator A5006329556 @default.
• W3087400259 creator A5009487344 @default.
• W3087400259 creator A5012617867 @default.
• W3087400259 creator A5016122215 @default.
• W3087400259 creator A5031216970 @default.
• W3087400259 creator A5032462496 @default.
• W3087400259 creator A5033073385 @default.
• W3087400259 creator A5036627244 @default.
• W3087400259 creator A5038914141 @default.
• W3087400259 creator A5047018311 @default.
• W3087400259 creator A5047928065 @default.
• W3087400259 creator A5049427985 @default.
• W3087400259 creator A5064856085 @default.
• W3087400259 creator A5064941466 @default.
• W3087400259 creator A5065205435 @default.
• W3087400259 creator A5068452218 @default.
• W3087400259 creator A5071962621 @default.
• W3087400259 creator A5073135494 @default.
• W3087400259 creator A5079523601 @default.
• W3087400259 creator A5080009159 @default.
• W3087400259 creator A5085150178 @default.
• W3087400259 creator A5086814640 @default.
• W3087400259 creator A5087936549 @default.
• W3087400259 creator A5088148467 @default.
• W3087400259 date "2020-11-01" @default.
• W3087400259 modified "2023-09-30" @default.
• W3087400259 title "Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group" @default.
• W3087400259 cites W1147404897 @default.
• W3087400259 cites W13575375 @default.
• W3087400259 cites W1985012922 @default.
• W3087400259 cites W2053292153 @default.
• W3087400259 cites W2056952913 @default.
• W3087400259 cites W2065464657 @default.
• W3087400259 cites W2071899049 @default.
• W3087400259 cites W2119147717 @default.
• W3087400259 cites W2120113475 @default.
• W3087400259 cites W2143901303 @default.
• W3087400259 cites W2228849275 @default.
• W3087400259 cites W2239959579 @default.
• W3087400259 cites W2282026400 @default.
• W3087400259 cites W2310716991 @default.
• W3087400259 cites W2430862255 @default.
• W3087400259 cites W2469109222 @default.
• W3087400259 cites W2529212447 @default.
• W3087400259 cites W2558507146 @default.
• W3087400259 cites W2565192467 @default.
• W3087400259 cites W2567632597 @default.
• W3087400259 cites W2742627598 @default.
• W3087400259 cites W2760635695 @default.
• W3087400259 cites W2761878534 @default.
• W3087400259 cites W2885077490 @default.
• W3087400259 cites W2885605795 @default.
• W3087400259 cites W2894631140 @default.
• W3087400259 cites W2902706178 @default.
• W3087400259 cites W2922237910 @default.
• W3087400259 cites W2948436219 @default.
• W3087400259 cites W3016696556 @default.
• W3087400259 doi "https://doi.org/10.1016/s2352-3026(20)30291-x" @default.
• W3087400259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32971036" @default.
• W3087400259 hasPublicationYear "2020" @default.
• W3087400259 type Work @default.
• W3087400259 sameAs 3087400259 @default.
• W3087400259 citedByCount "11" @default.
• W3087400259 countsByYear W30874002592020 @default.
• W3087400259 countsByYear W30874002592021 @default.
• W3087400259 countsByYear W30874002592022 @default.
• W3087400259 countsByYear W30874002592023 @default.
• W3087400259 crossrefType "journal-article" @default.
• W3087400259 hasAuthorship W3087400259A5003078312 @default.
• W3087400259 hasAuthorship W3087400259A5006329556 @default.
• W3087400259 hasAuthorship W3087400259A5009487344 @default.
• W3087400259 hasAuthorship W3087400259A5012617867 @default.
• W3087400259 hasAuthorship W3087400259A5016122215 @default.
• W3087400259 hasAuthorship W3087400259A5031216970 @default.
• W3087400259 hasAuthorship W3087400259A5032462496 @default.
• W3087400259 hasAuthorship W3087400259A5033073385 @default.
• W3087400259 hasAuthorship W3087400259A5036627244 @default.
• W3087400259 hasAuthorship W3087400259A5038914141 @default.
• W3087400259 hasAuthorship W3087400259A5047018311 @default.
• W3087400259 hasAuthorship W3087400259A5047928065 @default.
• W3087400259 hasAuthorship W3087400259A5049427985 @default.
• W3087400259 hasAuthorship W3087400259A5064856085 @default.
• W3087400259 hasAuthorship W3087400259A5064941466 @default.
• W3087400259 hasAuthorship W3087400259A5065205435 @default.
• W3087400259 hasAuthorship W3087400259A5068452218 @default.
• W3087400259 hasAuthorship W3087400259A5071962621 @default.
• W3087400259 hasAuthorship W3087400259A5073135494 @default.
• W3087400259 hasAuthorship W3087400259A5079523601 @default.
• W3087400259 hasAuthorship W3087400259A5080009159 @default.
• W3087400259 hasAuthorship W3087400259A5085150178 @default.
• W3087400259 hasAuthorship W3087400259A5086814640 @default.
• W3087400259 hasAuthorship W3087400259A5087936549 @default.
• W3087400259 hasAuthorship W3087400259A5088148467 @default.
• W3087400259 hasBestOaLocation W30874002591 @default.
• W3087400259 hasConcept C126322002 @default.

• next